SYDNEY, AUSTRALIA: CSL Limited (ASX:CSL) has appointed Dr Paul McKenzie as Chief Executive Officer (CEO) and Managing Director of CSL from 6 March 2023.
Dr Paul McKenzie will succeed Mr Paul Perreault, who has suggested the Board of his intention to retire after serving 10 years within the role, and greater than 25 years with the company. Dr McKenzie has been appointed following a thorough course of conducted by the Board.
Currently serving as CSL’s Chief Operating Officer (COO), Dr McKenzie, will instantly join the Board of Directors as an Executive Director and can become CEO and Managing Director on 6 March 2023. Mr Perreault will step down as CEO and from the CSL Board of Directors on 6 March 2023 and he’ll stay with the corporate as a strategic adviser to help in an orderly transition till he retires on 6 September 2023.
Dr Paul McKenzie has greater than 30 years of management expertise within the worldwide biotechnology industry, together with managing complex organisations through compelling growth and transformation.
Since becoming a member of CSL as COO in 2019, Dr McKenzie has been accountable for optimising CSL’s operations in addition to rising the CSL Seqirus, CSL Plasma, and CSL Vifor businesses.
He transformed CSL’s global end-to-end operations, superior CSL Seqirus’ differentiated portfolio strategy, and led CSL Plasma through COVID-19 challenges whereas surpassing plasma assortment volumes past pre-pandemic levels.
Prior to becoming a member of CSL, Dr McKenzie was Executive Vice President of Pharmaceutical Operations & Technology at Biogen. He additionally served in a vary of progressively senior level roles in R&D and manufacturing at Johnson & Johnson, Bristol-Myers Squibb and Merck.
CSL Limited Chair Dr Brian McNamee said, “Paul McKenzie is a patient-focused global chief with a demonstrated track record of main complex organizations and delivering excellent enterprise results. With his deep understanding of CSL’s strategy, tradition and operations, Paul is well positioned to lead CSL to its subsequent level of sustainable growth for our shareholders and the sufferers we serve across the world.”
Dr Paul McKenzie said, “CSL’s promise to save people’s lives through science has lengthy distinguished our company. I am excited, honoured and humbled for the chance to proceed constructing CSL’s legacy following the strong basis established by Paul Perreault over the final decade.
I look ahead to persevering with our momentum and engaging closely with the Board, our management team, 30,000 colleagues, and different stakeholders to serve sufferers and public well being across the world. We will proceed specializing in executing our 2030 strategy, investing in innovation, and proceed achieving sustainable and worthwhile growth.”